Resverlogix (TSX:RVX) Debt-to-Asset : 0.91 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Debt-to-Asset?

Resverlogix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$9.20 Mil. Resverlogix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Resverlogix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was C$10.08 Mil. Resverlogix's debt to asset for the quarter that ended in Mar. 2024 was 0.91.

Resverlogix Debt-to-Asset Historical Data

The historical data trend for Resverlogix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Debt-to-Asset Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.91

1.16

0.71

0.80

1.04

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	0.87	0.87	1.04	0.91

Competitive Comparison of Resverlogix's Debt-to-Asset

For the Biotechnology subindustry, Resverlogix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resverlogix's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Resverlogix's Debt-to-Asset falls into.

Resverlogix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Resverlogix's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.056	+	0)	/	8.746
	=	1.04

Resverlogix's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.195	+	0)	/	10.079
	=	0.91

Resverlogix (TSX:RVX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Resverlogix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Resverlogix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines